Millions are prescribed<unk>  (Xarelto) for atrial fibrillation, cardiac stents, stroke prevention, DVT/PE and ACS prophylaxis
Benefits: supposedly easier to dose, less monitoring than older anticoagulants
Downside: uncertainty regarding best mechanism of reversal in case of catastrophic intracranial or GI bleed
Multiple studies done since introduction of direct thrombin inhibitor (DTI) dabigatran and Factor Xa inhibitors<unk>  and apixaban to determine testing for supratherapeutic levels and best means of reversal, however no good trials that assessing human subjects who are potentially supratherapeutic and symptomatic
Rivaroxaban reversal
Bleeding secondary to other coagulopathy
Dabigatran reversal
Spontaneous bleeding
Warfarin reversal
Unfractionated heparin reversal
Anti-platelet agent reversal
Enoxaparin